Smithkline Beecham Corporation

Glaxosmithkline LLC

Amarjit Sab Randhawa

Darryl Lynn McDougald

John Albert Ray

Rodolfo Cadilla

Philip Stewart Turnbull

Andrew Lamont Larkin

Eugene Lee Stewart

Huiquiang Zhou

Katherine Stetson

Curt Dale Haffner

Steven Michael Reister

Michael Tolar Martin

David Norman Deaton

Dennis Heyer

Subba Reddy Katamreddy

James Martin Lenhard

David Igo

Michael Scott McClure

Daniel Patterson

Vicente Samano

Paul R Johnson

John Fred Eaddy, Iii

Huiqiang Zhou

Darryl Lynn Mcdougald

This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.

Chemical compounds

The present invention includes anhydrous crystalline forms of (2S,4S)-4-fluoro-1-[4-fluoro-&#x3b2;-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt.

[object Object]

Compounds of formula (I): with a variety of therapeutic uses, more particularly novel prodrugs that are particularly useful for delivering a parent compound for selective estrogen receptor modulation.

Triphenylethylene compounds as selective estrogen receptor modulators

The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility 

Pyrrolidines as dipeptidyl peptidase inhibitors

The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility.

Fluoropyrrolidines as dipeptidyl peptidase inhibitors

Growing community of inventors

Durham, NC, United States of America

Amarjit Sab Randhawa